After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure

Authors Max Gelman
Published July 13, 2020
Topics
Keywords
Source View at Endpoints News

Less than a year after inking a $100 million licensing deal with German giant Bayer, Dewpoint Therapeutics has scored another big-time contract, this time with Merck. And this collaboration came together in a particularly unusual fashion.

Merck and Dewpoint have agreed on a partnership that will provide the pharma giant with access to the Boston-based biotech’s biomolecular condensate technology in order to develop treatments, and potentially a cure, for the HIV virus. Dewpoint, in turn, will receive up to $305 million in upfront and milestone payments as well as royalties for any approved product…

Join the conversation

Create an Account or Sign In to comment.